WO2011070592A3 - Novel sugar derivatives as sglt2 inhibitors - Google Patents

Novel sugar derivatives as sglt2 inhibitors Download PDF

Info

Publication number
WO2011070592A3
WO2011070592A3 PCT/IN2010/000796 IN2010000796W WO2011070592A3 WO 2011070592 A3 WO2011070592 A3 WO 2011070592A3 IN 2010000796 W IN2010000796 W IN 2010000796W WO 2011070592 A3 WO2011070592 A3 WO 2011070592A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
polymorphs
prodrugs
solvates
metabolites
Prior art date
Application number
PCT/IN2010/000796
Other languages
French (fr)
Other versions
WO2011070592A2 (en
Inventor
Rajesh Jain
Sanjay Trehan
Sastry V.R.S. Thungathurthi
Gurmeet Kaur Nanda
Jagattaran Das
Sitaram Kumar Magadi
Sudhir Kumar Sharma
Original Assignee
Panacea Biotec Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd. filed Critical Panacea Biotec Ltd.
Publication of WO2011070592A2 publication Critical patent/WO2011070592A2/en
Publication of WO2011070592A3 publication Critical patent/WO2011070592A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Abstract

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2). The invention also relates to the use of compounds of Formula I, their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof, for the manufacture of a medicament for the prophylaxis, amelioration and/or treatment of conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2) and the related diseases, disorders and conditions, in a subject in need thereof.
PCT/IN2010/000796 2009-12-09 2010-12-09 Novel sugar derivatives WO2011070592A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2553DE2009 2009-12-09
IN2553/DEL/2009 2009-12-09

Publications (2)

Publication Number Publication Date
WO2011070592A2 WO2011070592A2 (en) 2011-06-16
WO2011070592A3 true WO2011070592A3 (en) 2012-05-10

Family

ID=44145994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000796 WO2011070592A2 (en) 2009-12-09 2010-12-09 Novel sugar derivatives

Country Status (2)

Country Link
AR (1) AR079438A1 (en)
WO (1) WO2011070592A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013038429A2 (en) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Novel sglt inhibitors
WO2013090550A1 (en) 2011-12-15 2013-06-20 National Health Research Institutes Novel glycoside compounds
JP6058023B2 (en) 2011-12-15 2017-01-11 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Sulfonamide derivatives
CA2891773C (en) * 2012-11-20 2021-01-19 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1
EP4006017A4 (en) * 2019-07-26 2023-09-06 Medshine Discovery Inc. Sglt2/dpp4 inhibitor and application thereof
WO2022160737A1 (en) * 2021-01-26 2022-08-04 东宝紫星(杭州)生物医药有限公司 Crystal form of tetrahydropyran ring compound and preparation method therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027128A1 (en) * 1999-10-12 2001-04-19 Bristol-Myers Squibb Company C-aryl glucoside sglt2 inhibitors
WO2009026537A1 (en) * 2007-08-23 2009-02-26 Theracos, Inc. Benzylbenzene derivatives and methods of use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1213296E (en) 1999-08-31 2004-08-31 Kissei Pharmaceutical DERIVATIVES OF GLUCOPIRANOSILOXIPIRAZOLE MEDICAL COMPOSITIONS THAT CONTAIN THEM AND INTERMEDIARIES IN THEIR PRODUCTION
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
NZ524917A (en) 2000-09-29 2005-01-28 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
JP3915116B2 (en) 2000-11-02 2007-05-16 味の素株式会社 Novel pyrazole derivatives and therapeutic agents for diabetes containing them
CA2429833A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
JP4147111B2 (en) 2001-02-27 2008-09-10 キッセイ薬品工業株式会社 Glucopyranosyloxypyrazole derivative and its pharmaceutical use
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2672001A1 (en) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
WO2003000712A1 (en) 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
US7655633B2 (en) 2002-12-25 2010-02-02 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof
EP1980560B1 (en) 2003-03-14 2011-05-25 Astellas Pharma Inc. C-glycoside derivatives for the treatment of diabetes
JP2004300102A (en) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd Condensed heterocyclic derivative, pharmaceutical composition containing the same and its pharmaceutical application
JPWO2004089967A1 (en) 2003-04-01 2006-07-06 大正製薬株式会社 Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
JP2004359630A (en) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd Difluorodiphenylmethane derivative and its salt
JP4520988B2 (en) 2003-08-26 2010-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Glucopyranosyloxy-pyrazole, pharmaceutical compositions containing these compounds, their use and methods for their preparation
US7375113B2 (en) 2004-03-04 2008-05-20 Kissei Pharmaceutical Co., Ltd. Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
US7732596B2 (en) 2004-03-04 2010-06-08 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
JPWO2005095429A1 (en) 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 Phenol derivative, pharmaceutical composition containing it, and pharmaceutical use thereof
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (en) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methylidene-D-xylopyranosyl and oxo-D-xylopyranosyl-substituted phenyls, medicaments containing these compounds, their use and processes for their preparation
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
JP2008508213A (en) 2004-07-27 2008-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング D-glucopyranosyl-phenyl-substituted cyclics, pharmaceuticals containing such compounds, their use and methods for their production
AR051446A1 (en) 2004-09-23 2007-01-17 Bristol Myers Squibb Co C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2)
DE102004048388A1 (en) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-pyranosyl-substituted phenyls, pharmaceutical compositions containing them, their use and processes for their preparation
WO2006054629A1 (en) 2004-11-18 2006-05-26 Kissei Pharmaceutical Co., Ltd. 1-SUBSTITUTED-3-β-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
ES2314743T3 (en) 2004-12-16 2009-03-16 Boehringer Ingelheim International Gmbh BENEFIT DERIVATIVES REPLACED WITH GLUCOPIRANOSIL, MEDICATIONS CONTAINING THIS TYPE OF COMPOUNDS, ITS USE AND PROCEDURE FOR MANUFACTURING.
EP1856082B1 (en) 2005-02-23 2009-10-14 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1924571B1 (en) 2005-08-30 2010-10-13 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
JP2009167104A (en) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd Phenyl 5-thio glycoside compound
TW200812995A (en) 2006-05-19 2008-03-16 Taisho Pharmaceutical Co Ltd C-phenyl glycitol compound
TWI432446B (en) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd Fused ring spiroketal derivative and use thereof as anti-diabetic drug
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
WO2008020011A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
TWI499414B (en) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc Inhibitors of sodium glucose co-transporter 2 and methods of their use
UY30730A1 (en) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp CRYSTAL FORM OF HEMIHYDRATE 1- (B (BETA) -D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-TIENYLMETHYL] BENZENE
WO2008090570A1 (en) 2007-01-25 2008-07-31 Panacea Biotec Ltd Novel antimicrobials
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
CN104803957A (en) 2007-04-02 2015-07-29 泰拉科斯有限公司 Benzylic glycoside derivatives and methods of use
WO2009116090A2 (en) 2008-03-18 2009-09-24 Panacea Biotec Limited Novel antimicrobials
AU2009282739B2 (en) 2008-08-22 2014-04-03 Theracosbio, Llc Processes for the preparation of SGLT2 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027128A1 (en) * 1999-10-12 2001-04-19 Bristol-Myers Squibb Company C-aryl glucoside sglt2 inhibitors
WO2009026537A1 (en) * 2007-08-23 2009-02-26 Theracos, Inc. Benzylbenzene derivatives and methods of use

Also Published As

Publication number Publication date
AR079438A1 (en) 2012-01-25
WO2011070592A2 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
WO2013038429A3 (en) Novel sglt inhibitors
IL203448A (en) Azabiphenylaminobenzoic acid derivatives for use in the treatment or prevention of a pathological condition or disease susceptible to amelioration by inhibition of dhodh and pharmaceutical compositions comprising them
WO2012172566A3 (en) Novel sglt inhibitors
WO2009047798A3 (en) Acetamide derivatives as glucokinase activators, their process and medicinal applications
WO2012066578A3 (en) Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
NO20084931L (en) Pharmaceutical compositions
MX2008013583A (en) Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them.
WO2007048070A3 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
EP3363797A8 (en) Oral dosage form of apoptosis signal-regulating kinase inhibitors
WO2011070592A3 (en) Novel sugar derivatives as sglt2 inhibitors
NO20063693L (en) Connection and method of use
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
NO20080865L (en) Spirochromanone derivatives such as acetyl-coenzyme-A-carboxylase (ACC) inhibitors
WO2007127175A3 (en) Pharmaceutical compounds
NO20090723L (en) Condensed heterocyclic derivatives and methods of use
WO2007005668A3 (en) Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
PL2150530T3 (en) Substituted sulfonamide derivatives
WO2010045251A3 (en) Spiro-oxindole compounds and their use as therapeutic agents
TW200942536A (en) PIM kinase inhibitors and methods of their use
MX340013B (en) Benzoxazepin compounds selective for pi3k p110 delta and methods of use.
NO20076195L (en) New 2-azetidinone derivatives for the treatment of hyperlipidemic diseases
WO2009093269A9 (en) Novel heterocyclic compounds
WO2011056985A3 (en) Substituted heterocyclic compounds
MX2014000536A (en) 4 - piperidinyl compounds for use as tankyrase inhibitors.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10807393

Country of ref document: EP

Kind code of ref document: A2